Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of appropriate antimicrobial therapy on patient outcomes and antimicrobial use: a sub analysis of the DIANA Study Dataset.

Intensive care medicine·2026

Same author

Consensus statement on the definition, diagnostic criteria, and treatment of refractory septic shock using a Delphi methodology.

Medicina intensiva·2026

Same author

Management of severe infections by multi-resistant Gram-negative bacteria in critically ill patients.

Medicina intensiva·2026

Same author

[Clarification regarding vitamin K in relation to the article "Serum vitamin levels in critically ill patients and their relationship to prognosis"].

Nutricion hospitalaria·2026

Same author

Oncologic critical care: A new frontier in critical care medicine.

Medicina intensiva·2026

Same author

Diagnostic accuracy of SeptiCyte® RAPID to discriminate sepsis from non-infectious critical illness in patients meeting sepsis criteria according to sepsis-3 definition at ICU admission.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026

Search research articles

Related Experiment Video

Updated: Jan 21, 2026

Author Spotlight: A Comprehensive Protocol for Acinetobacter Biofilm Quantification, Assessment, and Visualization

Author Spotlight: A Comprehensive Protocol for Acinetobacter Biofilm Quantification, Assessment, and Visualization

Published on: August 4, 2023

How should we treat acinetobacter pneumonia?

Rosario Amaya-Villar¹, José Garnacho-Montero²

¹Intensive Care Clinical Unit, Hospital Universitario Virgen de Rocío.

Current Opinion in Critical Care

|July 24, 2019

Summary

Acinetobacter baumannii pneumonia is a serious nosocomial infection. While polymyxins show in-vitro activity, suboptimal lung concentrations necessitate exploring nebulized antibiotics and novel agents like cefiderocol.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Published on: May 6, 2014

Related Experiment Videos

Last Updated: Jan 21, 2026

Author Spotlight: A Comprehensive Protocol for Acinetobacter Biofilm Quantification, Assessment, and Visualization

Author Spotlight: A Comprehensive Protocol for Acinetobacter Biofilm Quantification, Assessment, and Visualization

Published on: August 4, 2023

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Published on: May 6, 2014

Area of Science:

Infectious Diseases
Pulmonology
Antimicrobial Resistance

Background:

Acinetobacter baumannii pneumonia is a significant cause of hospital-acquired infections, particularly in vulnerable patients.
High rates of carbapenem resistance limit treatment options, making empirical therapy crucial.
Inappropriate treatment is linked to increased mortality.

Purpose of the Study:

To review current epidemiology of Acinetobacter baumannii pneumonia.
To discuss therapeutic strategies, including adjunctive nebulized therapy.

Main Methods:

Literature review of recent data on Acinetobacter baumannii pneumonia.
Analysis of therapeutic options, focusing on polymyxins and nebulized antibiotics.

Main Results:

Polymyxins, particularly colistin and polymyxin B, exhibit high in-vitro activity against Acinetobacter baumannii.
Suboptimal lung concentrations of polymyxins support the use of combination or nebulized therapy.
Nebulized antibiotics may be beneficial for non-responsive cases or isolates with borderline colistin susceptibility.
Cefiderocol shows promise as a novel therapeutic option.

Conclusions:

Optimal treatment for multidrug-resistant Acinetobacter baumannii pneumonia remains undefined.
Further research, including randomized controlled trials, is essential to evaluate nebulized antibiotics.
Novel agents like cefiderocol warrant further investigation.